− Reduces Relapses, Disability Progression and Brain Lesions with a Favorable Safety Profile − Only Pegylated Interferon in MS, Dosed Once Every Two Weeks − Complements …
PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis
– Reduces Relapses, Disability Progression, and MRI Brain Lesions, with a Favorable Safety Profile Consistent with the Established Interferon Class – Initial Country Launches …
Sobi to review preclinical data to potentially add future haemophilia A candidate to collaboration agreement with Biogen Idec
June 17, 2014 On Friday, 13 June, Swedish Orphan Biovitrum AB’s (publ) (Sobi) received a data package from Biogen Idec regarding a preclinical Hemophilia A program based …
FDA Approves Biogen Idec’s ELOCTATE™, First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children
Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Infusions Every Three to Five Days Approval of Biogen Idec’s Second Innovative Hemophilia Therapy with …
Data from Biogen Idec’s Portfolio of Multiple Sclerosis Therapies and Pipeline Featured at Medical Congresses
Scientific Presentations Showcase Innovative MS Medicines and Experimental Therapies May 30, 2014 Biogen Idec today announced that more than 60 company-sponsored presentations highlighting key data from its …
Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate™ for Hemophilia A
Data Showed Twice-Weekly Prophylactic Dosing with ELOCTATE Maintained Low Bleeding Rates in Children Under Age 12 Study Meets Primary Objectives; Results Enable Regulatory Submission in …
FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart
Only Approved Treatment to Demonstrate Prolonged Clotting Factor Circulation in the Body – Approved for Adults and Children March 28, 2014 Today Biogen Idec announced that the U.S. …
Health Canada Approves Biogen Idec’s Long-Acting ALPROLIX Therapy for Hemophilia B
The Approval of ALPROLIX is First Significant Advance in Hemophilia B Treatment in More Than 17 Years March 21, 2014 Today Biogen Idec announced that Health Canada …
- Page 1 of 2
- 1
- 2